Derisking Topical Formulation Development: Manufacturing Chemist

Today the market for topical pharmaceuticals is valued at around $95 billion, with topical drug development efforts particularly focused on small molecules and biologics. Forecast to grow by $70 billion during the next 4–5 years, this is a fast-moving area in which cost-effective development is essential.

In this article, Dr Jon Lenn, Chief Technology Officer, and Professor Marc Brown, Chief Scientific Officer at MedPharm explore how multifactorial disease models can be deployed to make topical formulation development more efficient and increase their chances of success.

Read the full article in Manufacturing Chemist here.

About MedPharm

MedPharm is the world’s leading contract provider of topical and transdermal formulation development and manufacturing services. Our experts specialize in reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through cost-effective and industry-leading performance testing models. Well-established as the global leader in dermal and transdermal product development, MedPharm also offers innovative solutions for airway, ophthalmic, otic, ungual, and other topical preparations. With locations in both the US and the UK, MedPharm is the CDMO of choice for developers around the globe.